The promise and perils of HDAC inhibitors in neurodegeneration

Alessandro Didonna; Puneet Opal

doi:10.1002/acn3.147

The promise and perils of HDAC inhibitors in neurodegeneration

Alessandro Didonna, Puneet Opal^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Review article › peer-review

96 Scopus citations

Abstract

Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.

Original language	English (US)
Pages (from-to)	79-101
Number of pages	23
Journal	Annals of clinical and translational neurology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1002/acn3.147
State	Published - Jan 1 2015

ASJC Scopus subject areas

Clinical Neurology
General Neuroscience

Access to Document

10.1002/acn3.147

Cite this

@article{af6b619f151f424bb48ea0f7d57862be,

title = "The promise and perils of HDAC inhibitors in neurodegeneration",

abstract = "Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.",

author = "Alessandro Didonna and Puneet Opal",

note = "Publisher Copyright: {\textcopyright} 2015 American Neurological Association.",

year = "2015",

month = jan,

day = "1",

doi = "10.1002/acn3.147",

language = "English (US)",

volume = "2",

pages = "79--101",

journal = "Annals of clinical and translational neurology",

issn = "2328-9503",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

TY - JOUR

T1 - The promise and perils of HDAC inhibitors in neurodegeneration

AU - Didonna, Alessandro

AU - Opal, Puneet

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.

AB - Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.

UR - http://www.scopus.com/inward/record.url?scp=84929878466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929878466&partnerID=8YFLogxK

U2 - 10.1002/acn3.147

DO - 10.1002/acn3.147

M3 - Review article

C2 - 25642438

AN - SCOPUS:84929878466

SN - 2328-9503

VL - 2

SP - 79

EP - 101

JO - Annals of clinical and translational neurology

JF - Annals of clinical and translational neurology

IS - 1

ER -

The promise and perils of HDAC inhibitors in neurodegeneration

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this